Equities research analysts expect that Retrophin Inc (NASDAQ:RTRX) will announce earnings per share of ($0.08) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Retrophin’s earnings. The highest EPS estimate is $0.07 and the lowest is ($0.23). Retrophin posted earnings per share of $0.15 in the same quarter last year, which indicates a negative year over year growth rate of 153.3%. The business is scheduled to issue its next earnings results on Tuesday, November 6th.

On average, analysts expect that Retrophin will report full-year earnings of ($0.62) per share for the current fiscal year, with EPS estimates ranging from ($0.86) to ($0.37). For the next financial year, analysts forecast that the company will report earnings of ($0.03) per share, with EPS estimates ranging from ($0.14) to $0.09. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Retrophin.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.21). Retrophin had a negative return on equity of 23.47% and a negative net margin of 46.90%. The firm had revenue of $41.33 million for the quarter, compared to analyst estimates of $43.22 million. During the same period last year, the company posted $0.03 earnings per share. The firm’s quarterly revenue was up 6.5% compared to the same quarter last year.

RTRX has been the subject of several analyst reports. Zacks Investment Research raised Retrophin from a “sell” rating to a “hold” rating in a research note on Thursday, September 27th. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. Canaccord Genuity initiated coverage on Retrophin in a research note on Friday, August 17th. They issued a “buy” rating for the company. Finally, ValuEngine downgraded Retrophin from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 22nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $43.00.

RTRX stock traded up $1.38 during trading on Tuesday, reaching $26.01. 273,300 shares of the stock were exchanged, compared to its average volume of 341,327. Retrophin has a twelve month low of $20.09 and a twelve month high of $33.00. The company has a market cap of $1.17 billion, a P/E ratio of -17.34 and a beta of 1.09.

In other news, CEO Steve Aselage sold 12,000 shares of the stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $32.00, for a total value of $384,000.00. Following the completion of the sale, the chief executive officer now directly owns 257,883 shares of the company’s stock, valued at $8,252,256. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 3.67% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of RTRX. Quantbot Technologies LP purchased a new stake in shares of Retrophin during the first quarter valued at approximately $110,000. FNY Investment Advisers LLC purchased a new stake in shares of Retrophin during the second quarter valued at approximately $136,000. Sei Investments Co. purchased a new stake in shares of Retrophin during the second quarter valued at approximately $141,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Retrophin during the first quarter valued at approximately $206,000. Finally, Hartford Investment Management Co. purchased a new stake in shares of Retrophin during the second quarter valued at approximately $216,000.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.